



Press Release

Source: CLX Medical, Inc.

CLX Medical, Inc. Announces Resignation of CEO

Issued Tuesday March 24, 3:50 pm ET

MURRIETA, CA--(MARKET WIRE)--Mar. 24, 2009--CLX Medical, Inc. (Other OTC: CLXM), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced the resignation of CEO Vera Leonard, effective March 16, 2009.

“After having achieved my goal of successfully identifying and acquiring a FDA cleared, CLIA waived product that offers CLX the opportunity to become market leader in an important healthcare sector, I am returning to my personal business of executive coaching and leadership development,” commented Ms. Leonard. “I continue to believe that the ThyroTest product has a great future and wish CLX great success in the next steps of its launch.”

Chairman Patrick Edgerton stated, “We would like to thank Vera Leonard for her service to the company and wish her nothing but the best in her future endeavors.”

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, or other information is disclosed, please visit <http://www.clxinvestments.com/email.php>.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for chlamydia. CLX has also recently closed its acquisition of ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical’s control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
investors@clxmedical.com